Back to Search Start Over

Abstract 1788: A high-throughput chemical genetic screen reveals SALL4-induced metabolic vulnerabilities in cancer

Authors :
Giridharan Periyasamy
Bee Hui Liu
Li Chai
Yue Wu
Kol Jia Yong
May Yin Lee
Siyu Wang
Glenn Kunath Bonney
Justin L. Tan
Yoganathan Kanagasundaram
Atsushi Suzuki
Yun Shen Chan
Zi Hui Tan
John M. Asara
Zhi Han Lim
Tan Boon Toh
Chan-Shuo Wu
Nikki R. Kong
Feng Li
Hon Man Chan
Yock Young Dan
Guo-Dong Lu
Edward Kai-Hua Chow
Alicia Stein
Wai Leong Tam
Huck-Hui Ng
Lissa Hooi
Guo Hao Ng
Siew Bee Ng
Joanna Z. Yeo
Chung Yan Leong
Daniel Geoffrey Tenen
Matan Thangavelu Thangavelu
Hong Kee Tan
Kia Ngee Low
Mahmoud A. Bassal
Siming Ma
Source :
Cancer Research. 80:1788-1788
Publication Year :
2020
Publisher :
American Association for Cancer Research (AACR), 2020.

Abstract

Transcription factors are important drivers of cancer but the development of therapeutics against these factors has had limited success. We developed a stringent high-throughput chemical genetic screening platform to identify compounds that target oncogenic transcription factor SALL4 dependency in liver cancer. The platform comprises SALL4 low- and high-expressing endogenous and engineered isogenic liver cancer cell lines. Unexpectedly, from screening 21,575 natural product extracts, the top hits were four oxidative phosphorylation inhibitors that selectively reduced SALL4-dependent cell viability. The ATP synthase inhibitor oligomycin suppressed SALL4-expressing cancer in lung and liver cancer cell culture models, and in patient-derived xenograft models of liver cancer. Oligomycin also synergized with sorafenib, the standard-of-care targeted therapy in liver cancer, to effectively suppress SALL4-driven tumorigenesis in vivo. When aberrantly expressed in cancer, SALL4 binds ~50% of mitochondrial genes, including many oxidative phosphorylation genes, to predominantly upregulate their expression. SALL4 upregulation also alters the levels of oxidative phosphorylation-related metabolites and functionally increases oxidative phosphorylation activity. Application of our endogenous/isogenic transcription factor-screening platform revealed a therapeutically actionable oxidative phosphorylation vulnerability in SALL4-expressing cancers. Citation Format: Justin L. Tan, Feng Li, Joanna Z. Yeo, Kol Jia Yong, Mahmoud A. Bassal, Guo Hao Ng, May Yin Lee, Chung Yan Leong, Hong Kee Tan, Chan-Shuo Wu, Bee Hui Liu, Hon Man Chan, Zi Hui Tan, Yun Shen Chan, Siyu Wang, Zhi Han Lim, Tan Boon Toh, Lissa Hooi, Kia Ngee Low, Siming Ma, Nikki R. Kong, Alicia J. Stein, Yue Wu, Matan T. Thangavelu, Atsushi Suzuki, Giridharan Periyasamy, John M. Asara, Yock Young Dan, Glenn K. Bonney, Edward K. Chow, Guo-Dong Lu, Huck Hui Ng, Yoganathan Kanagasundaram, Siew Bee Ng, Wai Leong Tam, Li Chai, Daniel G. Tenen. A high-throughput chemical genetic screen reveals SALL4-induced metabolic vulnerabilities in cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1788.

Details

ISSN :
15387445 and 00085472
Volume :
80
Database :
OpenAIRE
Journal :
Cancer Research
Accession number :
edsair.doi...........dd90ae5e89b8c585e18c405d1916ad4c